Abcam, ab217109, Alexa Fluor® 647 Anti-METTL3 antibody [EPR18810]

Size: 100µL
Rabbit Recombinant Monoclonal METTL3 antibody - conjugated to Alexa Fluor® 647. Suitable for ICC/IF and reacts with Human samples. Cited in 3 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18810,
Isotype:IgG,
Conjugation:Alexa Fluor® 647,
Excitation/Emission:Ex: 650nm, Em: 665nm,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The METTL3 protein also known as methyltransferase like 3 plays an important role in the modification of RNA. It is a component of the N6-adenosine-methyltransferase complex and is responsible for introducing the m6A mark on RNA. The molecular weight of METTL3 is approximately 70 kDa. This protein shows high expression in the human central nervous system and various cancer tissues indicating its broad significance.
Biological function summary
METTL3 contributes to the post-transcriptional regulation of gene expression by modulating m6A methylation. It functions as part of a complex with METTL14 and Wilms’ tumor 1-associating protein (WTAP) to execute this modification. The m6A mark influences RNA stability splicing export and translation affecting cellular processes significantly.
Pathways
METTL3 operates within critical pathways such as the mRNA stability and processing pathway. In these pathways METTL3 interacts with proteins like METTL14 and YTH domain-containing proteins which are important for m6A reader function. Together they regulate RNA processing events that influence cellular function and adaptation.
METTL3 associates strongly with cancer development and neurological disorders. In cancers alterations in METTL3 expression affect tumor progression and metastasis impacting oncogenes like MYC. In the realm of neurological disorders METTL3’s role in m6A modification affects RNA regulation aligning it with proteins like FTO which also participate in m6A demethylation processes. Understanding these connections highlights METTL3 as a potential target for therapeutic interventions.